Literature DB >> 7510297

Epitope mapping and functional studies with three monoclonal antibodies to the c-kit receptor tyrosine kinase, YB5.B8, 17F11, and SR-1.

L K Ashman1, H J Bühring, G W Aylett, V C Broudy, C Müller.   

Abstract

Three monoclonal antibodies (MAbs) to the human c-kit receptor tyrosine kinase (P145c-kit), derived in independent laboratories, have been extensively used in studies of c-kit expression and the role of its ligand, steel factor (SLF), in hemopoiesis and mast cell differentiation and function. In this study, the relationship between the epitopes they identify, and their effects on SLF binding, receptor internalization, and signal transduction are compared. Epitope mapping studies carried out on the high P145c-kit-expressing cell line HEL-DR showed that SR-1 identifies an epitope independent of those bound by YB5.B8 and 17F11, while the latter two antibodies bound to distinct but interacting epitopes. SR-1 potently blocked the binding of SLF to P145c-kit on these cells and also on cells of the factor-dependent line MO7e. In contrast, YB5.B8 and 17F11 had minimal effects on ligand binding. Conversely, SLF partially blocked the binding of SR-1 and YB5.B8 to cells, while binding of 17F11 was actually enhanced by SLf on some target cells. Preincubation of HEL-DR and MO7e cells with MAbs prior to exposure to SLF revealed that 17F11 itself brought about partial down-regulation of P145c-kit and did not inhibit SLF-mediated down-regulation. SR-1 caused minimal down-regulation and inhibited SLF-mediated receptor internalization. YB5.B8 had minimal effects on either cell line in this assay. To determine whether the antibodies had any agonist activity, they were compared with SLF for their ability to bring about receptor phosphorylation in intact MO7e cells. All three antibodies induced detectable tyrosine phosphorylation with 17F11 being the most effective, while YB5.B8 was the least effective. Finally, the ability of the antibodies to influence the proliferation of the MO7e cells was examined. As expected, SR-1 potently inhibited the proliferative response to SLF, while 17F11 weakly inhibited and YB5.B8 had negligible effect. In the absence of SLF both 17F11 and YB5.B8 displayed very weak but reproducible agonist activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510297     DOI: 10.1002/jcp.1041580321

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice.

Authors:  Hye-Sook Kwon; Aaron C Logan; Akanksha Chhabra; Wendy W Pang; Agnieszka Czechowicz; Keri Tate; Alan Le; Jessica Poyser; Roger Hollis; Benjamin V Kelly; Donald B Kohn; Irving L Weissman; Susan S Prohaska; Judith A Shizuru
Journal:  Blood       Date:  2019-01-07       Impact factor: 22.113

2.  Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells.

Authors:  Tao-Sheng Li; Ke Cheng; Konstantinos Malliaras; Rachel Ruckdeschel Smith; Yiqiang Zhang; Baiming Sun; Noriko Matsushita; Agnieszka Blusztajn; John Terrovitis; Hideo Kusuoka; Linda Marbán; Eduardo Marbán
Journal:  J Am Coll Cardiol       Date:  2012-03-06       Impact factor: 24.094

3.  HL-60 myeloid leukaemia cells acquire immunostimulatory capability upon treatment with retinoic acid: analysis of the responding population and mechanism of cytotoxic lymphocyte activation.

Authors:  S M Geary; L K Ashman
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

4.  A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.

Authors:  Maria B Lebron; Laura Brennan; Christopher B Damoci; Marie C Prewett; Marguerita O'Mahony; Inga J Duignan; Kelly M Credille; James T DeLigio; Marina Starodubtseva; Michael Amatulli; Yiwei Zhang; Kaben D Schwartz; Douglas Burtrum; Paul Balderes; Kris Persaud; David Surguladze; Nick Loizos; Keren Paz; Helen Kotanides
Journal:  Cancer Biol Ther       Date:  2014-06-12       Impact factor: 4.742

5.  KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

Authors:  Cheryl A London; Heather L Gardner; Sarah Rippy; Gerald Post; Krista La Perle; Linda Crew; Lori Lopresti-Morrow; Andrew J Garton; Gerald McMahon; Theresa M LaVallee; Richard Gedrich
Journal:  Clin Cancer Res       Date:  2016-11-04       Impact factor: 12.531

6.  Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.

Authors:  Marianne Le Gall; Ronan Crépin; Madeline Neiveyans; Christian Auclair; Yongfeng Fan; Yu Zhou; James D Marks; André Pèlegrin; Marie-Alix Poul
Journal:  Mol Cancer Ther       Date:  2015-09-10       Impact factor: 6.261

7.  Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice.

Authors:  Wendy W Pang; Agnieszka Czechowicz; Aaron C Logan; Rashmi Bhardwaj; Jessica Poyser; Christopher Y Park; Irving L Weissman; Judith A Shizuru
Journal:  Blood       Date:  2019-02-11       Impact factor: 25.476

8.  Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Authors:  Badreddin Edris; Stephen B Willingham; Kipp Weiskopf; Anne K Volkmer; Jens-Peter Volkmer; Thomas Mühlenberg; Kelli D Montgomery; Humberto Contreras-Trujillo; Agnieszka Czechowicz; Jonathan A Fletcher; Robert B West; Irving L Weissman; Matt van de Rijn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII.

Authors:  Athena L Russell; Chengyu Prince; Taran S Lundgren; Kristopher A Knight; Gabriela Denning; Jordan S Alexander; Jaquelyn T Zoine; H Trent Spencer; Shanmuganathan Chandrakasan; Christopher B Doering
Journal:  Mol Ther Methods Clin Dev       Date:  2021-05-05       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.